Haematologica (Apr 2012)

Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin’s lymphoma

  • Chuanhui Xu,
  • Wouter Plattel,
  • Anke van den Berg,
  • Nele Rüther,
  • Xin Huang,
  • Miao Wang,
  • Debora de Jong,
  • Hans Vos,
  • Gustaaf van Imhoff,
  • Andreas Viardot,
  • Peter Möller,
  • Sibrand Poppema,
  • Arjan Diepstra,
  • Lydia Visser

DOI
https://doi.org/10.3324/haematol.2011.056101
Journal volume & issue
Vol. 97, no. 4

Abstract

Read online

Background The c-Met signaling pathway regulates a variety of biological processes, including proliferation, survival and migration. Deregulated c-Met activation has been implicated in the pathogenesis and prognosis of many human malignancies. We studied the function and prognostic significance of c-Met and hepatocyte growth factor protein expression in patients with classical Hodgkin’s lymphoma.Design and Methods Expression of c-Met and its ligand, hepatocyte growth factor, were determined by immunohistochemistry. Prognostic values were defined in cohorts of German and Dutch patients with classical Hodgkin’s lymphoma. Functional studies were performed on Hodgkin’s lymphoma cell lines.Results Expression of c-Met was detected in the tumor cells of 52% (80/153) of the patients and expression of its ligand, hepatocyte growth factor, in 8% (10/121) of the patients. c-Met expression correlated with a 5-year freedom from tumor progression of 94%, whereas lack of expression correlated with a 5-year freedom from tumor progression of 73% (P